ArticleScientific reports2018

Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.

Yan Weng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.